Cover Image
市場調查報告書

Compugen Ltd.- 產品平台分析

Compugen Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 204908
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Compugen Ltd.- 產品平台分析 Compugen Ltd. - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 48 Pages
簡介

Compugen, Ltd. (Compugen) 著重於治療性蛋白質和單株抗體的開發,致力於癌症和心臟血管的疾病、免疫相關疾病的治療藥開發。

本報告提供Compugen Ltd.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Compugen Ltd.的基本資料

Compugen Ltd.概要

  • 主要資訊
  • 企業資料

Compugen Ltd.:R&D概要

  • 主要的治療範圍

Compugen Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Compugen Ltd.:開發中產品概況

Compugen Ltd.

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Compugen Ltd.:藥物簡介

  • CGEN-15001
  • CGEN-15021
  • CGEN-15031
  • CGEN-15051
  • CGEN-15091
  • CGEN-25008
  • CGEN-25009
  • CGEN-25068
  • CGEN-856S
  • Monoclonal Antibody to Inhibit CGEN-15022 for Epithelial Cancer
  • Monoclonal Antibody to Inhibit CGEN-15049 for Cancer
  • Monoclonal Antibody to Target CGEN-15001T for Cancer
  • Recombinant Proteins for Autoimmune and Inflammatory Diseases
  • CGEN-15029
  • Monoclonal Antibody 2 for Oncology
  • Monoclonal Antibody 3 for Oncology
  • Monoclonal Antibody 4 or Oncology
  • Monoclonal Antibody 5 for Oncology
  • Monoclonal Antibody Conjugate 1 for Cancer
  • Monoclonal Antibody Conjugate 2 for Cancer
  • Monoclonal Antibody for Cancer
  • Monoclonal Antibody to Inhibit CGEN-15027 for Cancer
  • Monoclonal Antibody to Inhibit CGEN-15052 for Cancer
  • Monoclonal Antibody to Inhibit CGEN-15092 for Oncology
  • Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma

Compugen Ltd.:開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Compugen Ltd.:最近的開發平台趨勢

Compugen Ltd.:暫停中的計劃

Compugen Ltd.:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08034CDB

Summary

Global Markets Direct's, 'Compugen Ltd. - Product Pipeline Review - 2016', provides an overview of the Compugen Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Compugen Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Compugen Ltd.
  • The report provides overview of Compugen Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Compugen Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Compugen Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Compugen Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Compugen Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Compugen Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Compugen Ltd. Snapshot
    • Compugen Ltd. Overview
    • Key Information
    • Key Facts
  • Compugen Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Compugen Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Compugen Ltd. - Pipeline Products Glance
    • Compugen Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
    • Compugen Ltd. - Drug Profiles
    • CGEN-15001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-15021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-15031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-15051
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-15091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-25009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-856S
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CGEN-15049 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CGEN-15052 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CGEN-15092 for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 to Inhibit CGEN-15029 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Target B7/CD28 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 3 to Target B7/CD28 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 4 to Target B7/CD28 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 5 to Target B7/CD28 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CGEN-15027 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Compugen Ltd. - Pipeline Analysis
    • Compugen Ltd. - Pipeline Products by Target
    • Compugen Ltd. - Pipeline Products by Molecule Type
    • Compugen Ltd. - Pipeline Products by Mechanism of Action
  • Compugen Ltd. - Recent Pipeline Updates
  • Compugen Ltd. - Dormant Projects
  • Compugen Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Compugen Ltd., Key Information
  • Compugen Ltd., Key Facts
  • Compugen Ltd. - Pipeline by Indication, 2016
  • Compugen Ltd. - Pipeline by Stage of Development, 2016
  • Compugen Ltd. - Monotherapy Products in Pipeline, 2016
  • Compugen Ltd. - Out-Licensed Products in Pipeline, 2016
  • Compugen Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Compugen Ltd. - Preclinical, 2016
  • Compugen Ltd. - Discovery, 2016
  • Compugen Ltd. - Pipeline by Target, 2016
  • Compugen Ltd. - Pipeline by Molecule Type, 2016
  • Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Compugen Ltd. - Recent Pipeline Updates, 2016
  • Compugen Ltd. - Dormant Developmental Projects,2016
  • Compugen Ltd., Subsidiaries

List of Figures

  • Compugen Ltd. - Pipeline by Indication, 2016
  • Compugen Ltd. - Pipeline by Stage of Development, 2016
  • Compugen Ltd. - Monotherapy Products in Pipeline, 2016
  • Compugen Ltd. - Pipeline by Target, 2016
  • Compugen Ltd. - Pipeline by Molecule Type, 2016
  • Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top